---
layout: default
title: Valproic Acid
parent: Model Prediction Only (L5)
nav_order: 1280
evidence_level: L5
indication_count: 10
---

# Valproic Acid
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Valproic Acid: From Antiseizure Use to Trigeminal Nerve Neoplasm

## One-Sentence Summary

Valproic acid is a marketed antiseizure drug. The licence records in this pack do not list approved indication text, so this description rests on the epilepsy literature in the pack.
The TxGNN model predicts it may be effective for **trigeminal nerve neoplasm**, but there are **0 clinical trials** and only **1 publication**, and that paper is not about a neoplasm.

## Quick Overview

| Item | Content |
|------|------|
| Predicted New Indication | Trigeminal nerve neoplasm |
| TxGNN Prediction Score | 99.97% |
| Evidence Level | L5 (model prediction only) |
| US Market Status | ✓ Marketed |
| Number of NDAs | 20 (all listed entries are ANDA generics) |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Valproic acid is a marketed antiseizure drug. The only mechanistic link to a tumour indication is speculative: valproate inhibits histone deacetylases (HDACs), which gives it a preclinical antineoplastic rationale.

The link between the original use (seizure control) and a nerve tumour is weak. The very high TxGNN score does not reflect any supporting clinical data. The single retrieved paper is a case series on Sturge-Weber syndrome, a neurocutaneous vascular syndrome rather than a neoplasm, so it is not direct evidence for this indication.

## Clinical Trial Evidence

Currently no related clinical trials registered.

## Literature Evidence

| PMID | Year | Type | Journal | Key Findings |
|------|-----|------|------|---------|
| [9157801](https://pubmed.ncbi.nlm.nih.gov/9157801/) | 1997 | Case series | Anales espanoles de pediatria | Review of 14 Sturge-Weber syndrome cases over 25 years, covering clinical features, evolution and treatment response. Not a neoplasm study, so it is not direct evidence. |

## US Market Information

Four distinct authorizations are listed. One (ANDA075782) appears twice in the record.

| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---------|------|------|-----------|
| ANDA075782 | Valproic Acid (Chartwell RX) | Solution | Not specified in the record |
| ANDA073178 | Valproic Acid (ANI Pharmaceuticals) | Solution | Not specified in the record |
| ANDA075379 | Valproic Acid (PAI Pharma) | Solution | Not specified in the record |
| ANDA073484 | Valproic Acid (Vangard Labs) | Capsule, liquid filled | Not specified in the record |

## Safety Considerations

Please refer to the package insert for safety information.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This prediction is model-only (L5). No trials were found, and the one retrieved paper concerns a different, non-neoplastic condition. A high TxGNN score alone is not sufficient to proceed.

**To proceed, the following is needed:**
- The package insert warnings and contraindications. This is a blocking gap that prevents safety screening.
- Mechanism of action data, for example from DrugBank, to test the HDAC-inhibition hypothesis in this tumour type.
- Preclinical or clinical studies of valproate specifically in trigeminal nerve tumours.

**Other candidates in the same pack:** two other predictions have stronger support (L3, "Research Question"). These are **trigeminal neuralgia**, with older small clinical studies and reviews describing valproate as a second-line or adjunct option, and **visual epilepsy**. Visual epilepsy largely falls within valproate's existing antiseizure class rather than being true repurposing. Both are better candidates than the neoplasm prediction for further evaluation.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

